| Dr Megan N Landis, MD | |
|
1263 Hospital Dr Nw Ste 240, Corydon, IN 47112-2174 | |
| (812) 738-4251 | |
| Not Available |
| Full Name | Dr Megan N Landis |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 16 Years |
| Location | 1263 Hospital Dr Nw Ste 240, Corydon, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558525485 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 45356 (Kentucky) | Secondary |
| 207N00000X | Dermatology | 01070947A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harrison County Hospital | Corydon, IN | Hospital |
| Memorial Hospital And Health Care Center | Jasper, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harrison County Hospital | 9032007208 | 36 |
News Archive
Innovative neuroscience research and expanded clinical care have been launched at the new Center of Excellence on Mood Disorders at The University of Texas Medical School at Houston.
The U.S. Food and Drug Administration announced today that a federal judge has approved a consent decree of permanent injunction against Ben Venue Laboratories, Inc., and three of its corporate officers for failing to comply with current good manufacturing practice requirements as required by federal law.
Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.
Salix Pharmaceuticals, Ltd. today announced the closing of its offering of $690 million aggregate principal amount of 1.5% convertible senior notes due 2019, which includes the exercise in full of the initial purchasers' overallotment option.
The philosopher Gerhard Thonhauser investigates the behavior of spectators at sports events to help him better understand group dynamics.
› Verified 6 days ago
| Entity Name | Harrison County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790892727 PECOS PAC ID: 9032007208 Enrollment ID: O20040406000076 |
News Archive
Innovative neuroscience research and expanded clinical care have been launched at the new Center of Excellence on Mood Disorders at The University of Texas Medical School at Houston.
The U.S. Food and Drug Administration announced today that a federal judge has approved a consent decree of permanent injunction against Ben Venue Laboratories, Inc., and three of its corporate officers for failing to comply with current good manufacturing practice requirements as required by federal law.
Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.
Salix Pharmaceuticals, Ltd. today announced the closing of its offering of $690 million aggregate principal amount of 1.5% convertible senior notes due 2019, which includes the exercise in full of the initial purchasers' overallotment option.
The philosopher Gerhard Thonhauser investigates the behavior of spectators at sports events to help him better understand group dynamics.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Megan N Landis, MD Po Box 38, Corydon, IN 47112-0038 Ph: (812) 738-4251 | Dr Megan N Landis, MD 1263 Hospital Dr Nw Ste 240, Corydon, IN 47112-2174 Ph: (812) 738-4251 |
News Archive
Innovative neuroscience research and expanded clinical care have been launched at the new Center of Excellence on Mood Disorders at The University of Texas Medical School at Houston.
The U.S. Food and Drug Administration announced today that a federal judge has approved a consent decree of permanent injunction against Ben Venue Laboratories, Inc., and three of its corporate officers for failing to comply with current good manufacturing practice requirements as required by federal law.
Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.
Salix Pharmaceuticals, Ltd. today announced the closing of its offering of $690 million aggregate principal amount of 1.5% convertible senior notes due 2019, which includes the exercise in full of the initial purchasers' overallotment option.
The philosopher Gerhard Thonhauser investigates the behavior of spectators at sports events to help him better understand group dynamics.
› Verified 6 days ago